Guessing Dr. Head got a lot of attention when he m
Post# of 110
(Total Views: 931)
Posted On: 05/10/2018 1:19:15 PM
Guessing Dr. Head got a lot of attention when he made his trip to Boston. Guess that's why this article came out...
May 10th 2018 - The Best Stock Investment For 2018 Is OncBioMune Pharmaceuticals (OBMP)
Follow @WarrenBuffetHQ OncBioMune Pharmaceuticals (OBMP) specializes in innovative cancer treatment therapies. It's lead vaccine product, ProscaVax™ for prostate cancer has had SPECTACULAR results and could become the standard of care for prostate cancer. Clinical trials have been so successful they have now been fast tracked and are taking place at the very heart of Pfizer (PFE) and Harvard Medical School collaboration Beth Israel Deaconess Medical Center.
https://askwarrenbuffet.blogspot.com/2018/02/...s.html?m=1
And nope, $OBMP didn't pay a cent for that either.
And here's just a taste of our potential, just a matter of getting through Phase 2 though a deal could certainly spark earlier. It is possible we get some serious funding before the trial even starts. That would be excellent but I usually see the deals at least after interim data, phase 2 or phase 3.
$1.6 billion transaction will bolster Lilly's clinical portfolio with ARMO's lead immuno-oncology asset, pegilodecakin, which is being studied in multiple tumor types
https://finance.yahoo.com/news/lilly-announce...00916.html
May 10th 2018 - The Best Stock Investment For 2018 Is OncBioMune Pharmaceuticals (OBMP)
Follow @WarrenBuffetHQ OncBioMune Pharmaceuticals (OBMP) specializes in innovative cancer treatment therapies. It's lead vaccine product, ProscaVax™ for prostate cancer has had SPECTACULAR results and could become the standard of care for prostate cancer. Clinical trials have been so successful they have now been fast tracked and are taking place at the very heart of Pfizer (PFE) and Harvard Medical School collaboration Beth Israel Deaconess Medical Center.
https://askwarrenbuffet.blogspot.com/2018/02/...s.html?m=1
And nope, $OBMP didn't pay a cent for that either.
Quote:
DISCLAIMER
This is a private independent blog dedicated to helping small investors by highlighting stocks that the publisher considers to be extremely undervalued. The publisher has never accepted payment in any form to feature or recommend any stock ever!
The publisher is not affiliated with any executives, owners, brokers, promoters or analysts. The publisher is not a registered investment adviser. Readers and subscribers should not view information found within this domain as offering personalized, legal, tax, accounting, stock or investment-related advice.
Ask Warren Buffet is a parody blog, the publisher is not associated with Warren Buffett. The use of Warren Buffett quotes, images or any likeness in our posts are for entertainment and inspirational purposes and are not to be interpreted as support for the stock or support for any blog post by Warren Buffett. He is in no way affiliated with our blog or stock selections that our publisher views as the Best Stock Investments for 2018.
And here's just a taste of our potential, just a matter of getting through Phase 2 though a deal could certainly spark earlier. It is possible we get some serious funding before the trial even starts. That would be excellent but I usually see the deals at least after interim data, phase 2 or phase 3.
$1.6 billion transaction will bolster Lilly's clinical portfolio with ARMO's lead immuno-oncology asset, pegilodecakin, which is being studied in multiple tumor types
https://finance.yahoo.com/news/lilly-announce...00916.html
(0)
(0)